An index of frontier and emerging AI labs.
Bio / AI drug discovery
Generative AI drug-discovery lab training models on DNA, RNA, protein, and small-molecule data for pharma discovery workflows. Raised a $25M Series A led by Bessemer in January 2026.
| Name | Converge Bio |
|---|---|
| Space | Bio / AI drug discovery |
| Founded | 2023 |
| Latest valuation | — |
| Stage | — |
| Status | active |
| HQ | Boston / Tel Aviv |
| Founders | Dov Gertz |
| Website | https://www.convergebio.com |
| Careers | — |
| — | |
| X / Twitter | — |
No funding events recorded.
No founders recorded yet. Submit info.
| Date | Type | Title | Source |
|---|---|---|---|
| 2026-06-14 | added | Converge Bio added to tracker | — |
No sources cited.
| Lab | Valuation | Founded |
|---|---|---|
| Isomorphic Labs | >$15B | 2021 |
| Xaira Therapeutics | ~$4B | 2024 |
| insitro | ~$2.5B | 2018 |
| Generate Biomedicines | ~$2B | 2018 |
| Recursion | ~$1.75B (mkt cap) | 2013 |
| Chai Discovery | $1.3B | 2024 |
| Earendil Labs | ~$1B | 2023 |
| EvolutionaryScale | >$1B | 2024 |